BiomX, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders Equity (Details Textual)

Stockholders Equity (Details Textual) $ / shares in Units, $ in Thousands			1 Months Ended					12 Months Ended
	Jan. 08, 2019 USD ($) shares	Dec. 11, 2018 USD ($) shares	Oct. 02, 2020 $ / shares shares	Mar. 25, 2020 Employees $ / shares shares	Dec. 18, 2018 USD ($) $ / shares shares	Nov. 28, 2018 USD ($) $ / shares shares	Oct. 28, 2018 shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($) Employees consultants $ / shares shares	Dec. 31, 2018 USD ($) shares	Mar. 10, 2021 shares	Jan. 02, 2021 shares	Oct. 28, 2019	Nov. 30, 2017 shares	May 31, 2017 $ / shares shares
Common stock, authorized								60,000,000	60,000,000
Common stock, issued								23,270,337	22,862,835
Common stock, par value \| $ / shares								$ 0.0001	$ 0.0001
Common stock, outstanding								23,264,637	22,862,835
Issuance of remaining common stock								60,041
Preferred stock, par value \| $ / shares								$ 0.0001	$ 0.0001
Preferred stock, shares authorized								1,000,000
Equity incentive plan, description								On May 5, 2020, the Board of Directors approved the grant of 79,000 options without consideration to four employees, under the 2019 Plan. These options were granted at an exercise price of $5.59 per share with a vesting period of four years.
Share based compensation expenses \| $								$ 1,384	$ 732
Unrecognized compensation expense \| $								2,657	2,308
Recognized expense income \| $								$ 233	241
Issuance of warrants								236,552
Warrants, description								a. 177,414 upon the filing of a patent application covering any Discovered Target or a Product (both as defined in the 2017 License Agreement). In 2020 the warrants were cancelled following termination of the 2017 License Agreement, b. 118,277 upon achievement of the earlier of the following milestone by the Company: (i) execution of an agreement with a pharmaceutical company with respect to the commercialization of any of the Company's licensed technology or the Consulting IP or a Product (both defined in the 2017 License Agreement) or (ii) the filing of a patent application covering any Discovered Target (as defined in the 2017 License Agreement) or a Product. In the case of termination of the 2017 License Agreement after the second anniversary thereof, and provided that none of the aforementioned milestones has been attained prior to such termination, the warrants will vest upon such termination. As of December 31, 2020, 118,277 warrants were vested as the 2017 License Agreement was terminated after the second anniversary with no milestone have been attained. c. 59,139 upon completion of a Phase 1 clinical trial in respect of a Product (as defined in the 2017 License Agreement). In 2020 the warrants were cancelled following the termination of the 2017 License Agreement.
Public warrants, description								● in whole and not in part; ● at a price of $0.01 per warrant; ● at any time during the exercise period; ● upon a minimum of 30 days' prior written notice of redemption; ● if, and only if, the last sale price of the Company's Common Stock equals or exceeds $16.00 per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.
Market sales agreement, description								Pursuant to a registration statement on Form S-3 declared effective by the Securities and Exchange Commission on December 11, 2020, the Company entered into an Open Market Issuance Sales Agreement ("ATM Agreement") with Jefferies LLC. ("Jefferies"), which provides that, upon the terms and subject to the conditions and limitations in the ATM Agreement, the Company may elect, from time to time, to offer and sell shares of Common Stock having an aggregate offering price of up to $50,000 through Jefferies acting as sales agent. During the year ended December 31, 2020, the Company sold 10,176 shares of Common Stock under the ATM Agreement, at an average price of $6.07 per share, raising aggregate net proceeds of approximately $60, after deducting an aggregate commission of 3%. The Company recorded issuance expenses of $158.
Total value of granted options \| $								$ 3,752	$ 1,395
Expenses recognized over period								2 years
Subsequent Event [Member]
Common stock, issued												930,813
Shares of issued warrants											362,444
Shares issued											362,383
New Incentive Plan [Member]
Grant options \| $ / shares									$ 1,000
Equity incentive plan, description									The aggregate number of shares of Common Stock that may be delivered pursuant to the 2019 Plan will automatically increase on January 1 of each year, commencing on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to four percent (4%) of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year.
Stock Options [Member]
Common stock shares									74,581
Grant options \| $ / shares									$ 527,716
Grant approved			32,000	814,700					704,669
Employees consideration \| Employees				65					22
Employees consideration, description				one consultant, four senior officers (one of whom is also a consultant), and six directors under the 2019 Plan.
Non-tradable options									79,630
Consideration consultants \| consultants									2
Exercise price \| $ / shares			$ 6.44	$ 6.21					$ 1.34
IPO [Member]
Offering price \| $ / shares					$ 10.00
Total gross proceeds \| $					$ 70,000
Consummated initial public offering					7,000,000
Price Per Share \| $ / shares					$ 11.50
Retained transaction \| $					$ 60,100
Private Placement [Member]
Aggregate warrants shares					2,900,000
Yeda [Member]
Shares of issued warrants														7,615
Founder [Member]
Shares of issued warrants														2,974
BiomX Israel [Member]
Exchange for common shares							15,069,058
Shares outstanding, percentage													65.00%
Earnout shares, description								A. 2,000,000 additional shares of the Company's Common Stock if the daily volume weighted average price of the Company's Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2022 is greater than or equal to $16.50 per share. B. 2,000,000 additional shares of the Company's Common Stock if the daily volume weighted average price of the Company's Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2024 is greater than or equal to $22.75 per share C. 2,000,000 additional shares of the Company's Common Stock if the daily volume weighted average price of the Company's Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2026 is greater than or equal to $29.00 per share.
License Agreement [Member]
Price Per Share \| $ / shares															$ 0.0001
Warrants to purchase common stock															591,382
Series A Preferred Stock [Member]
Preferred stock, shares issued										3,028,990
Sale of stock, consideration \| $										$ 13,000
Series A Preferred Stock [Member] \| Share Purchase Agreement [Member]
Preferred stock, shares issued						5,478,985
Preferred stock, par value \| $ / shares						$ 0.0001
Sale of stock, consideration \| $		$ 30,155				$ 31,955
Shares issued		205,750
Series A Preferred Stock [Member] \| Share Purchase Agreement [Member] \| Investors [Member]
Sale of stock, consideration \| $	$ 1,800
Shares issued	308,628					4,964,607